Komori
Mochida Pharmaceutical (4534) · InitiativeCited as achieved

Rebuilding of the Head Office Building

First written in FY2020. 2 of 5 entries say "Advanced", first in FY2021. Latest entry: FY2023-Q3.

5entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020AdvancedFY2021 – FY2023-Q22020: 120202021: 120212022: 220222023: 12023
Same theme, other companies
Rebuilding of the Head Office BuildingA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2023-Q3Cited as achievedAnnual report

    「Head office Shinjuku-ku, Tokyo Head office building reconstruction September 2022」

    The company is reiterating that the head office building reconstruction was completed in September 2022 as a completed property, plant and equipment item.
  2. FY2023-Q2AchievedAnnual report

    「Head office Shinjuku-ku, Tokyo Head office building reconstruction September 2022」

    The head office building reconstruction, which commenced in May 2020 and was scheduled for completion in September 2022, has been completed.
  3. FY2022AdvancedAnnual report

    「Head office building Reconstruction 3,200 1,680 Internal funds May 2020 September 2022」

    For the head office building reconstruction, the amount paid to date has increased from ¥323 million to ¥1,680 million, and the scheduled completion date has been updated from October 2022 to September 2022.
  4. FY2021AdvancedAnnual report

    「Head office (Shinjuku-ku, Tokyo) Head office building reconstruction Total cost: ¥3,200 million Amount paid to date: ¥323 million Internal funds Start: May 2020 Completion: October 2022」

    For the head office building reconstruction, the amount paid to date has increased from ¥82 million to ¥323 million, indicating that the plan is progressing. The total cost of ¥3,200 million and scheduled completion in October 2022 remain unchanged.
  5. FY2020First statedAnnual report

    「Filing company: Head office (Shinjuku-ku, Tokyo) Head office building reconstruction Total cost: ¥3,200 million Amount paid to date: ¥82 million Internal funds Start: May 2020 Completion: October 2022」

    The company discloses for the first time a plan to reconstruct its head office building, with a total cost of ¥3,200 million, work commencing in May 2020 and completion scheduled for October 2022.
Moved together

"Lifecycle Management and Strategic Alliances" moved the same way as this thread, in the same document, in 2 of its 5 moves.

22222★12345
  1. ★This thread
  2. 1Lifecycle Management and Strategic Alliances2×
  3. 2Progress in Regulatory Approvals, Applications, and Clinical Development2×
  4. 3Strengthening the Development Pipeline through Open Innovation2×
  5. 4Expansion of the Dermatology-Based Skincare Business2×
  6. 5Balance Between Retained Earnings and Shareholder Returns2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Mochida Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.